Alzheimer’s and Parkinson’s Diseases: Recent Developments

Front Matter....Pages i-xx
Visual Processing in Alzheimer’s Disease....Pages 1-11
Stereopsis in Alzheimer’s Disease: Measuring Binocular Eye Movement....Pages 13-17
Visual Cognition and Language Function in Alzheimer’s Disease....Pages 19-24
Variables Affecting Visuospatial Primary Memory Defect in Alzheimer’s Disease: Preliminary Data....Pages 25-28
Articulatory Deficits in Parkinson’s and Huntington’s Disease: An Acoustic Analysis....Pages 29-32
Alzheimer’s Disease and Parkinson’s Disease with Dementia: Comparison of Cortical Blood Flow Demonstrated by Three-Dimensional Surface Display....Pages 33-38
Correlation between Severity of Dementia and Decreased Cerebral Blood Flow in Alzheimer’s Disease and Senile Dementia of the Alzheimer’s Type....Pages 39-44
Cerebral Blood Flow at Rest and During Cognitive Activation in Patients with Moderate Dementia of Alzheimer’s Type....Pages 45-49
Usefulness of Monitoring Left Ventricular Function by an Ambulatory Radionuclide Detector (VEST) in Patients with Parkinson’s Disease and Postural Hypotension....Pages 51-54
Frontal Dysfunction and Memory Deficit in Depression and Parkinson’s Disease....Pages 55-61
Cellular Acetylcholine Receptor Expression in the Brain of Patients with Alzheimer’s and Parkinson’s Dementia....Pages 63-67
The Contribution of Non-Dopaminergic Pathology to Cognitive, Motor and Affective Disability in Parkinson’s Disease....Pages 69-76
Clinical, Pathological and Neurochemical Characteristics of Lewy Body Dementia....Pages 77-86
Creutzfeldt-Jakob Disease (CJD) is Not an Infectious Disease....Pages 87-93
Normal Production of the Amyloid β -Protein and the Pathogenesis of Alzheimer’s Disease....Pages 95-97
Modulation of APP Processing by Neurotransmission....Pages 99-103
Amyloid Precursor Protein (APP) Gene Expression is Controlled by a NFkB/Rel Related Protein....Pages 105-110
Specific Cleavage of β -Amyloid Precursor Protein by an Integral Membrane Metalloendopeptidase....Pages 111-118
Amyloidogenic Fragments of Amyloid Precursor Protein in Cells Cultured under Leupeptin....Pages 119-125
A Leptomeningeal Protease Releasing the β Protein from the β Protein Precursor of Alzheimer’s Disease....Pages 127-130
Cell Surface Receptor Mediated Control of Amyloid Precursor Protein Secretion: Involvement of Pleiotropic Signal Transduction Cascades....Pages 131-139
Role of β -Amyloid in the Diagnosis of Neurodegenerative Diseases: Diffuse Lewy Body Disease Versus Alzheimer’s Disease....Pages 141-147
Identification and Role of Non-Beta Components of Senile Plaque Amyloid in Alzheimer’s Disease....Pages 149-155
 β -Amyloid-Protein Immunoreactivity in Skin is Not a Reliable Marker of Alzheimer’s Disease: An Autopsy Controlled Study....Pages 157-163
Metabolic and Functional Changes in βAPP Overexpressing Mouse Neuronal Cell Line: Muscarinic Receptor-Mediated Calcium Influx....Pages 165-170
Effect of Ciliary Neurotrophic Factor on β -Amyloid Precursor Protein mRNA Expression....Pages 171-175
Tau and High Molecular Weight Microtubule Associated Proteins in Aluminum-Induced Neurofibrillary Pathology....Pages 177-188
Phenotypes and Genotypes of Apolipoprotein E in Japanese Patients with Late-Onset Sporadic Alzheimer’s Disease, Vascular Dementia, Down’s Syndrome or Parkinson’s Disease....Pages 189-196
Risk Factors of Senile Dementias: Comparisons of Alzheimer’s Disease and Vascular Dementias....Pages 197-201
Predictors of Institutional Care in Parkinson’s Disease....Pages 203-204
Parkinson’s Disease: Biometrics Towards Nature-Nurture Puzzles....Pages 205-210
Pathogenesis of Nigral Cell Death in Parkinson’s Disease....Pages 211-216
Complement Components and GFAP Immunoreactivity within Alzheimer and Pathologic Aged Cortex....Pages 217-222
Aluminum Neurotoxicity and Alzheimer’s Disease....Pages 223-229
Distribution and Regulation of Interleukin 1- β Converting Enzyme in Rat and Man....Pages 231-238
Localization and Density of Transferrin Binding Sites in the Nigrostriatal System of Control Subjects and Patients with Parkinson’s Disease....Pages 239-244
Positron Emission Tomography (PET) Studies with Ligands for Cholinergic Receptors in the Human Brain....Pages 245-249
Effect of Cholinergic Enhancers on Basal Forebrain Function Governing Cortical Cerebral Blood Flow....Pages 251-257
Acetylcholinesterase is Not a Protease: Implications for Alzheimer’s Disease....Pages 259-266
Does Tacrine Increase Acetylcholine Release from the Hippocampus?....Pages 267-273
Aging-Induced Changes in the Autoregulation of Acetylcholine Release in the Rat Brain....Pages 275-282
The Effect of Acetylcholinesterase Inhibitors on Acetylcholinesterase in Senile Plaque, Normal Human or Rat Brain, Human Erythrocyte or Rat Skeletal Muscle....Pages 283-290
Quantity and Quality Changes of G Protein in Dementia of the Alzheimer Type....Pages 291-296
Calcium Binding Proteins in the Septo-Hippocampal System of the Aged Rat....Pages 297-302
Calcium Binding Proteins Differentiate Midbrain Dopaminergic Systems in Humans....Pages 303-306
Enzymatic and Genetic Analysis of Cu/Zn Superoxide Dismutase in Non-Familial Alzheimer’s Disease....Pages 307-309
Oxidative Stress and the Loss of Receptor Sensitivity in Aging....Pages 311-317
Oxygen Toxicity Induces Apoptotic Neuronal Death in Cultured Rat Hippocampal Neurons....Pages 319-326
Histochemical Demonstration of Monoamine Oxidase Activity in the Mouse Striatal Cholinergic Neurons and Marked Species Variations among Rodent Striata....Pages 327-331
Cell Wall-Defective Forms of Nocardia Asteroides Require Tetrahydrobiopterin for Their Growth....Pages 333-337
The Cholinotoxin AF64A Differentially Attenuates in Vitro Transcription of the Human Cholinesterase Genes....Pages 339-345
Transient Alterations in the in Vivo Levels of Cholinesterase mRNAS Suggest Differential Adjustment to Cholinotoxic Stimuli....Pages 347-352
Failure of the Neurotrophic ACTH(4–10) Analogue (BIM 22015) to Attenuate the AF64A-Induced Cholinergic Lesion in Rat Hippocampus....Pages 353-358
Combined Nicotinic and Muscarinic Cholinergic and Serotonergic Blockade Selectively Impair Acquisition of Spatial Navigation....Pages 359-369
Effect of JTP-2942, a Novel TRH Analogue, on Cognitive Function and Learning in Rodents....Pages 371-377
Effects of a Novel TRH Analog, JTP-2942, on Cholinergic and Monoaminergic Neurons in the Brain....Pages 379-382
Effect of Cortical Ischemic Damage on Primate Nucleus Basalis....Pages 383-387
Intracerebroventricular Injection of Streptozotocin — An Animal Model for Sporadic Alzheimer’s Disease?....Pages 389-393
Neuropathological Studies on Strains of Senescence Accelerated Mouse with Age Related Deficits in Learning and Memory....Pages 395-400
Transgenic Rat and In-Vitro Studies of β-Amyloid Precursor Protein Processing....Pages 401-409
“Kangenkaryu”, Chinese Herb Medicine, Improved Several Symptoms in Animal Models....Pages 411-419
Catecholamine-Containing Biodegradable Microsphere Implants: An Overview of Experimental Studies in Dopamine-Lesioned Rats....Pages 421-427
Alzheimer Disease: Major Neurotransmitter Deficits. Can they be Corrected?....Pages 429-436
Recent Clinical Trials of Cholinomimetics for Patients with Alzheimer’s Disease in Japan....Pages 437-448
New M1 Agonists: Selective Signaling, Neurotrophic-Like and Cognitive Effects — Implications in the Treatment of Alzheimer’s Disease....Pages 449-455
Xanomeline: A Potent and Selective M1 Muscarinic Agonist in Vitro....Pages 457-461
Absorption, Distribution, Metabolism, and Elimination of Radiolabeled Xanomeline in Healthy Male Subjects....Pages 463-468
Single and Multiple Dose Safety, Pharmacodynamics and Pharmacokinetics of Xanomeline, a Novel Muscarinic M1 Agonist in Healthy Male Subjects....Pages 469-473
Safety, Tolerance, and Pharmacokinetics of Xanomeline Tartrate: A Novel Muscarinic M1 Agonist in Healthy Elderly Subjects....Pages 475-478
The Safety and Tolerance of Xanomeline Tartrate, an M1-Specific Cholinergic Agonist, in Patients with Alzheimer’s Disease....Pages 479-482
CI-1002, a Novel Anticholinesterase and Muscarinic Antagonist....Pages 483-490
Preclinical Evaluation of Linopirdine: Neurochemical and Behavioral Effects....Pages 491-498
New Radioligands for PET-Examination of Central Muscarinic Receptors....Pages 499-505
Gangliosides and Alzheimer’s Disease....Pages 507-512
Estrogen in Clinical Trials for Dementia of Alzheimer Type....Pages 513-523
MDL 72,974 A a Novel MAO-B Inhibitor: A European Multicentre Trial in Parkinson’s Disease as an Adjunct to Levodopa....Pages 525-530
Neuronal Grafting in Parkinson’s Disease....Pages 531-535
Environmentally-Derived Carbolinium Analogs of MPP + are Toxic to Dopaminergic Neurons in Vitro and in Vivo....Pages 537-543
Presence of N-Methylated β -Carbolinium Ions and Potential Neurotoxic Analogs of MPP + in the Brain and Cerebrospinal Fluid of Parkinsonian and Non-Parkinsonian Patients....Pages 545-552
Metabolic Bioactivation of Endogenous Isoquinolines as Dopaminergic Neurotoxins to Elicit Parkinson’s Disease....Pages 553-559
Effect of Selegiline Administration on the Urinary Excretion of Dopamine-Derived Tetrahydroisoquinoline Alkaloids in Parkinson’s Disease Patients....Pages 561-567
Inhibitory Effects of Endogenous Tetrahydroisoquinolines on Mitochondrial Respiration in Mouse Brain....Pages 569-574
Dopamine-Derived Isoquinolines as Dopaminergic Neurotoxins and Oxidative Stress....Pages 575-581
Effect of Chronic Administration of 1,2,3,4-Tetrahydroisoquinoline and Its Derivatives on the Monkey: Immunohistochemical Study....Pages 583-587
The in Vitro Formation of 1,3-Dimethyl-1,2,3,4-Tetrahydroisoquinoline, a Neurotoxic Metabolite of Amphetamines....Pages 589-597
A Novel Endogenous Amine, 1-Benzyl-1,2,3,4-Tetrahydroisoquinoline(1BnTIQ) in Parkinsonian CSF, and Its Toxicological Effect....Pages 599-604
Neurotrophic Factor Therapy of Alzheimer’s Disease....Pages 605-609
Potential Therapeutic Use of BDNF or NT-4/5 in Parkinson’s and Alzheimer’s Diseases....Pages 611-619
Loss of Growth Inhibitory Factor in Degenerative Disease....Pages 621-624
NGF Rescues Cholinergic Cell Bodies of the Primate Nucleus Basalis of Meynert and Induces Compensatory Synaptic Changes in Cortically-Lesioned Rats....Pages 625-632
Microglia Secrete Plasminogen Which Enhances the Maturation of Mesencephalic Dopaminergic Neurons in Vitro ....Pages 633-640
Indicators of Oxidative Stress in Aged Fischer 344 Rats: Potential for Neurotrophic Treatment....Pages 641-646
Regulation of Expression of the Low-Affinity NGF Receptor (p75LNGFR) Gene in Clonal Rat Pheochromocytoma PC12h-R Cells and Cultured Rat Basal Forebrain Cholinergic Neurons: Its Relation to Expression of the High-Affinity NGF Receptor ( trk A) Gene....Pages 647-654
Molecular Biology of Catecholamine Systems: Multiple Tyrosine Hydroxylases in Different Simian Species, and in Humans in Relation to Parkinson’s Disease....Pages 655-659
Population Diversity of Point Mutations in the Human AChE and BCHE Genes Predicts Variable Responses to Anticholinesterase Drugs....Pages 661-667
Inhibition of Excitatory Amino Acid-Induced Neurotoxicity by a Tau Antisense Oligonucleotide in Primary Culture of Cerebellar Granule Cells....Pages 669-675
Molecular Cloning of Human Growth Inhibitory Factor CDNA and Its Down-Regulation in Alzheimer’s Disease....Pages 677-683
Expression of Human Tyrosine Hydroxylase-Chloramphenicol Acetyltransferase (CAT) Fusion Gene in the Brains of Transgenic Mice as Examined by CAT Immunocytochemistry....Pages 685-692
Is the Point Mutation in Codon 331 of the Mitochondrial ND2 Gene Associated with Alzheimer’s Disease?....Pages 693-697
A Novel Gene Delivery System for Neuroactive Peptides in Brain Tissue....Pages 699-707
The Cholinergic Hypothesis of Geriatric Cognitive Dysfunction”: Consensus Meeting. January 24–25, 1993, Brescia, Italy....Pages 709-711
Back Matter....Pages 713-724